An NIH biosketch is the biographical sketch used to show that a key person has the training, positions, outputs, and scientific contribution needed for the proposed NIH work. For a startup, it should not read like a generic resume. It should help a reviewer trust that the named people can execute the research plan, manage risk, and produce credible evidence.
The NIH biosketch is a personnel document, but it has proposal consequences. If it is vague, the reader has to guess why the team is qualified. If it is overloaded with every job, award, and publication a person has ever held, the important signal disappears. The useful middle ground is a short, current, evidence-backed profile that maps each senior person to the work they will actually perform.
This guide is NIH-specific. If you are preparing an NSF proposal, use the NSF biosketch guide because the document set, SciENcv workflow, and related support documents differ. For the rest of the proposal structure, use grant proposal anatomy, grant proposal template, and how to write a grant application.
Quick answer: what the NIH biosketch does
The NIH biosketch answers one practical reviewer question: why should this person be trusted with this part of the work? It shows appointments, training, contributions, outputs, and relevant scientific context. In a startup application, it also helps translate commercial or engineering experience into NIH review language. A founder may have patents, prototypes, regulatory work, software systems, clinical collaborations, or pilot studies rather than a long academic publication record. The biosketch should make that evidence legible without pretending it is something else.
| Biosketch job | What the reviewer needs | Startup evidence that can help |
|---|---|---|
| Qualification | Can this person do the proposed work? | Prior R&D role, relevant technical leadership, domain publications, patents, prototypes, clinical or regulatory experience. |
| Role fit | Why is this person on this project? | Direct ownership of a work package, assay, model, device subsystem, data pipeline, or validation plan. |
| Contribution | What has this person already contributed? | A specific scientific, engineering, translational, or commercialization contribution tied to the proposal. |
| Credibility | Is the claim supported? | Outputs that can be named without exaggeration: papers, IP, datasets, pilot users, protocols, approvals, or technical milestones. |
The biosketch is not where you hide missing proposal logic. It cannot rescue a weak research strategy, an unclear milestone plan, or a budget that does not match the work. Its job is narrower and still important: it should make the team evidence easier to score.
NIH biosketch vs resume, other support, and proposal narrative
Teams often lose time because they treat every people-related artifact as the same document. A resume tells a broad career story. A biosketch tells a proposal-relevant qualification story. Other support helps NIH understand active and pending resources. The project narrative and research strategy explain the work itself. Mixing these artifacts creates confusion and can make an otherwise strong team look careless.
| Artifact | Primary purpose | What not to put there |
|---|---|---|
| NIH biosketch | Show a key person's qualifications and relevant contributions. | A full career resume or unrelated awards. |
| Resume or CV | Broad career history for general use. | Do not submit as a biosketch unless the funder explicitly allows that format. |
| Other support | Disclose active and pending support where required. | Do not use it to argue scientific merit. |
| Research strategy | Explain aims, approach, significance, innovation, and methods. | Do not bury team qualifications that belong in personnel documents. |
| Facilities/resources | Show institutional, lab, equipment, and environment capacity. | Do not use it as a biography for individual contributors. |
- Keep the biosketch role-specific. If the person owns computational biology, manufacturing scale-up, assay development, or device validation, the document should make that ownership obvious.
- Keep other support separate. Active funding and commitments are not the same as qualification evidence, even when they involve similar projects.
- Keep the proposal narrative focused on the work. Refer to the team when it supports feasibility, but do not turn methods sections into biography.
- Keep old templates under control. NIH format pages and SciENcv should be the source of truth, not a stale document copied from a previous submission.
Who needs an NIH biosketch
The exact personnel requirements depend on the NIH opportunity, form set, and application type, so the current NIH instructions should control. As a practical planning rule, prepare biosketch material for every person whose qualifications materially affect reviewer confidence: principal investigator or project lead, senior/key people, scientific founders, technical leads, and collaborators whose expertise is essential to the work. Do not wait until final assembly to discover that a contributor lacks a complete profile.
Startup teams should be especially deliberate about external advisors and subcontractors. If a named collaborator is central to a clinical validation plan, animal study, regulatory strategy, or specialized manufacturing process, the team should know early whether that person needs a biosketch, letter, subcontract material, or another support document. The goal is not to create more paperwork; it is to prevent the proposal from depending on unnamed credibility.
| Person type | Likely question | Planning action |
|---|---|---|
| Scientific founder | Can they lead the scientific direction? | Prepare a focused biosketch tied to the proposal's technical core. |
| Engineering lead | Can they build or validate the system? | Translate engineering outputs into evidence reviewers can understand. |
| Clinical or regulatory advisor | Is the translational plan credible? | Clarify role, effort, and required support documents early. |
| Academic collaborator | What unique resource or expertise do they bring? | Coordinate biosketch, facilities, support letters, and subcontract material. |
| Commercial operator | Are they relevant to research execution? | Include only when their role affects the funded work. |
NIH biosketch format and SciENcv workflow
NIH format and common-form instructions evolve, so the safest workflow is to start from NIH's current biosketch pages and SciENcv rather than a local template. SciENcv helps assemble biographical sketch information in an approved structure, but it does not decide which achievements are most relevant. That judgment still belongs to the applicant.
A good workflow starts outside the tool. List the people, map each person to proposal responsibilities, collect evidence, then create or update the SciENcv profile. If the team opens SciENcv first, the process can become clerical: fill every field, paste old text, export, and move on. Reviewers do not reward clerical completeness if the relevance is unclear.
- Start with the role map. Write one sentence explaining why each person matters to the proposed work before assembling biography details.
- Collect evidence before formatting. Gather publications, patents, datasets, technical milestones, regulatory interactions, clinical collaborations, and prior grants before editing prose.
- Use current instructions. NIH format pages and SciENcv should decide structure; the proposal should decide emphasis.
- Review the export. A generated document can still have weak logic, duplicated claims, or stale contributions.
What to prepare before you open SciENcv
The strongest biosketches are prepared from a short evidence inventory. This matters for founders because startup evidence often sits outside standard academic buckets. A founder may have built a prototype, validated a model in a customer environment, led a regulated product plan, or managed an interdisciplinary engineering team. Those facts can matter, but only if they are written in a way that connects to the NIH project.
A useful evidence inventory is not a dumping ground. It should separate evidence that proves scientific judgment, evidence that proves execution ability, and evidence that proves access to a necessary environment or resource. A founder may be tempted to include every accelerator, customer conversation, or investor milestone. Most of that belongs elsewhere or nowhere. The biosketch should privilege evidence that changes reviewer confidence about the proposed research.
| Evidence to collect | Why it matters | How to use it |
|---|---|---|
| Current appointment and role | Shows responsibility and authority. | Use concise language that matches the person's proposal role. |
| Relevant training | Shows foundation for the work. | Include only training that supports the proposed science or execution. |
| Selected outputs | Shows proof, not just aspiration. | Choose outputs tied to the proposal, not the longest list. |
| Prior contribution | Shows a pattern of progress. | Describe a contribution in plain language before listing details. |
| Project responsibility | Shows fit to the work plan. | Align to aims, milestones, or technical tasks. |
Do not over-polish away specifics. Phrases like "experienced entrepreneur" or "world-class scientist" are weaker than a concrete, relevant contribution. If the person led development of a diagnostic workflow, managed a preclinical validation study, or created a dataset used in the proposal, say that plainly and connect it to the planned work.
The contribution language should also be calibrated to the evidence stage. A founder can say they led prototype development if the prototype exists; they should not imply the prototype has clinical proof if the project is designed to generate that proof. A biosketch can be confident without being inflated. In NIH review, credibility often comes from showing exactly where the current evidence ends and where the proposed work begins.
For interdisciplinary teams, the biosketch set should show coverage across the actual risks. If the project needs biology, engineering, data analysis, clinical context, and commercialization planning, the personnel documents should not all emphasize the same founder story. Each document should make a different capability visible so the reviewer can see a complete team rather than a collection of impressive but overlapping biographies.
This is why biosketch review should happen with the project lead, not only with an administrator. The project lead knows which risks matter and which claims need support. An administrator can catch formatting problems; the project lead can catch relevance problems. Strong applications need both reviews.
How to make contributions and positions scoreable
A biosketch becomes scoreable when each claim gives the reviewer something to verify or infer. The reviewer should not need to translate job titles into proposal relevance. If a founder is the technical lead, explain the technical domain. If a collaborator is essential, explain the resource or expertise they provide. If prior work reduces risk, name the risk.
| Weak wording | Stronger wording | Why it works |
|---|---|---|
| Experienced in AI for health. | Led development of the model architecture used in the pilot analysis described in Aim 1. | Connects experience to the proposed work. |
| Successful founder. | Built and managed the engineering team that produced the current prototype and validation dataset. | Turns status into execution evidence. |
| Published researcher. | Authored papers on the assay method that underpins the proposed feasibility study. | Shows relevance, not just output count. |
| Advisor to the company. | Provides clinical protocol input and access to the workflow constraints tested in Aim 2. | Explains why the advisor matters. |
This is also where restraint matters. Do not claim that a prototype, pilot, or unpublished dataset proves more than it does. NIH reviewers are used to calibrated claims. The biosketch should make real strengths easier to see, not inflate evidence beyond what the application can defend.
NIH biosketch example logic for a startup team
Imagine a deeptech company applying for NIH funding to validate a sensor-enabled diagnostic workflow. The scientific founder owns the assay design, the engineering lead owns the hardware and data pipeline, and an academic collaborator provides clinical workflow expertise. A weak set of biosketches would list each person's career history. A stronger set would show why each person reduces a different execution risk.
The founder's biosketch would emphasize prior work on the biological signal and feasibility data. The engineering lead's biosketch would show prototype development, measurement reliability, and data-handling experience. The collaborator's biosketch would show disease-area expertise, protocol design, and access to realistic workflow constraints. None of these documents needs to repeat the full research strategy; together, they should make the team logic credible.
| Role | Main risk addressed | Biosketch emphasis |
|---|---|---|
| Scientific founder | Does the biology support the method? | Relevant assay, prior studies, scientific contribution, interpretation role. |
| Engineering lead | Can the system be built and measured reliably? | Prototype outputs, measurement pipeline, validation environment, technical ownership. |
| Clinical collaborator | Will the study reflect real workflow needs? | Clinical domain expertise, protocol input, recruitment or site context if applicable. |
Common NIH biosketch mistakes
Most biosketch problems are not formatting errors; they are relevance errors. A perfectly formatted document can still be weak if it does not help the reviewer understand why the person is qualified for the proposed work. Conversely, a concise biosketch with strong relevance can support the proposal even when the applicant is not a traditional academic lab.
- Using a resume in disguise. A long career list makes the reviewer search for the relevant signal. Select and frame evidence around the application.
- Hiding startup evidence. Patents, prototypes, pilots, datasets, regulatory work, and engineering milestones can matter when they connect to the project.
- Overstating maturity. Do not imply that early feasibility data proves clinical, commercial, or regulatory outcomes the project has not reached.
- Ignoring related documents. Other support, facilities, letters, and the research strategy should tell a consistent story without repeating the same text.
- Waiting until the deadline. Biosketch gaps reveal missing collaborators, unclear roles, and stale profiles late in the process.
The practical fix is to review biosketches alongside the work plan. For each key person, ask: what will they do, what evidence shows they can do it, and where does that evidence appear? If the answer is not visible, revise before final formatting.
For startup applications, this review should happen before collaborator paperwork is finalized. A missing or weak biosketch can reveal that a named advisor has no defined role, that a founder is covering too many technical risks, or that a subcontractor is essential but under-described. Fixing those issues early can improve the research strategy, budget, and letters at the same time. The biosketch is short, but it often exposes whether the team plan is actually coherent.
The final version should feel current, selective, and aligned. Current means it follows the latest NIH instructions. Selective means it favors evidence that supports the proposed work. Aligned means the biosketch, research strategy, budget, and collaborator documents all describe the same team model.
If a sentence does not help a reviewer understand capability, role, or relevance, cut it.